TABLE 1.
Study demographics, Montreal classification, and disease behavior for inflammatory bowel diseases (IBD) patient samples in this study.
| Characteristics | Total IBD | CD | UC |
| Total no. of patients | 362 | 202(55.8%) | 160(44.2%) |
| Age (years) | 40 ± 15.0(13–77) | 36 ± 13.2(14–70) | 46 ± 15.2(13–77) |
| Male, n(%) | 242(67%) | 135(67%) | 107(67%) |
| Current smokers, n (%) | 45(12.4%) | 23(11.4%) | 22(13.8%) |
| infection Clostridium difficile | 69(19.1%) | 38(18.8%) | 31(19.4%) |
| Duration of disease (median, months) | 36(0–360) | 33(0–340) | 41(0–360) |
| Abscess or fistula | 35(9.7%) | 30(14.9%) | 5(3.1%) |
| HBsAg (positive) | 24(6.6%) | 15(7.4%) | 9(5.6%) |
| Montreal A (1:2:3) | 13(6.4%):130(64.4%): 59(29.2%) |
||
| Montreal L (1:2:3) | 72(35.6%):40(19.8%): 90(44.6%) |
||
| Montreal B (1:2:3) | 122(60.4%):52(25.7%): 28(13.9%) |
||
| Montreal E (1:2:3) | 23(14.4%):43(26.9%): 94(58.8%) |
||
| Previous intestinal surgery | 15(4.1%) | 12(5.9%) | 3(1.9%) |
| Disease activity | |||
| Active | 167(46.1%) | 91(45.0%) | 76(47.5%) |
| Inactive | 195(53.9%) | 111(55.0%) | 84(52.5%) |
| Medications | |||
| Steroid therapy | 78(21.5%) | 48(23.8%) | 30(18.8%) |
| Aminosalicylate therapy | 294(81.2%) | 171(84.7%) | 123(76.9%) |
| Immunosuppressive therapy | 108(53.5%) | 87(43.1%) | 21(13.1%) |
| Biologics | 125(34.5%) | 101(50.0%) | 24(15.0%) |
UC, ulcerative colitis; CD, Crohn’s disease. Montreal A: 1 = age ≤ 16 years at diagnosis, 2 = 17–40 years, 3 = age > 40 years. Montreal L:1 = location ileum, 2 = colonic, 3 = ileocolonic. Montreal B: 1 = non-stricturing, non-penetrating, 2 = stricturing, 3 = penetrating; Montreal E: 1 = ulcerative proctitis, 2 = left sided (distal) ulcerative colitis, 3 = pancolitis. Montreal E:1 = proctitis, 2 = left-sided colitis, 3 = extensive colitis.